An MVA vaccine overcomes tolerance to human p53 in mice and humans

Cancer Immunology, Immunotherapy

Volumn 56, Issue 8, 2007, Pages 1193-1205

  Song, Guang Yun ^a   Gibson, Glen ^a   Haq, Wahajul ^a   Huang, Eric C C ^a   Srivasta, Tumul ^a   Hollstein, Monica ^b   Daftarian, Pirouz ^a   Wang, Zhongde ^a   Diamond, Don ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Animal models of cancer; Cancer vaccines; Immune response to cancer; p53

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; PEPTIDE LIBRARY; PROTEIN P53; VACCINIA VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER PATIENT; CARCINOMA CELL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPERIMENTAL MOUSE; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34248531439     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0270-3     Document Type: Article

References (47)

1. Hainaut P, Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137
2. Zhu X, Belmont HJ, Price-Schiavi S, Liu B, Lee HI, Fernandez M, et al (2006) Visualization of p53(264-272)/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor. J Immunol 176:3223-3232
3. Sherman LA, Theobald M, Morgan D, Hernandez J, Bacik I, Yewdell J, et al (1998) Strategies for tumor elimination by cytotoxic T lymphocytes. Crit Rev Immunol 18:47-54
4. Ruiz PJ, Wolkowicz R, Waisman A, Hirschberg DL, Carmi P, Erez N, et al (1998) Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med 4:710-712
5. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ (1996) p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 93:4781-4786
6. Gabrilovich DI, Cunningham HT, Carbone DP (1996) IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J Immunother Emphasis Tumor Immunol 19:414-418
7. Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L (1998) The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 16:208-215
8. Parajuli P, Pisarev V, Sublet J, SteVel A, Varney M, Singh R, et al (2001) Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Cancer Res 61:8227-8234
9. Tuting T, DeLeo AB, Lotze MT, Storkus WJ (1997) Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 27:2702-2707
10. Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, et al (2001) Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer Gene Ther 8:87-98
11. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, et al (2000) High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 60:5508-5513
12. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ (2000) Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 87:253-260
13. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van HT, van dB, et al (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695-704
14. + cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 49:603-612
15. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, et al (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183:1357-1365
16. Noguchi Y, Richards EC, Chen YT, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219-2223
17. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, et al (2003) CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170:3401-3407
18. Kuball J, Schuler M, Antunes FE, Herr W, Neumann M, Obenauer-Kutner L, et al (2002) Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 9:833-843
19. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, et al (2004) Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 53:633-641
20. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 12:878-887
21. Hernandez J, Lee PP, Davis MM, Sherman LA (2000) The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 164:596-602
22. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, et al (2000) Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 165:5938-5944
23. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, et al (2006) Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-Cell epitopes. J Virol 80:4717-4728
24. Dorrell L, Yang H, Ondondo B, Dong T, di GK, Suttill A, et al (2006) Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J Virol 80:4705-4716
25. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, Niesters HG, et al (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-3709
26. Daftarian P, Song G, Ali S, Faynsod M, Longmate J, Diamond DJ, et al (2004) Two distinct pathways of immunomodulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 64:5407-5414
27. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A (1974) MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 99:2386-2392
28. Moorthy VS, McConkey S, Roberts M, Gothard P, Arulanantham N, Degano P, et al (2003) Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 21:2004-2011
29. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9:729-735
30. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, Sutter G, et al (2003) Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22:21-29
31. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, et al (2004) Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27:240-253
32. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20:320-328
33. Wang Z, La Rosa C, Mekhoubad S, Lacey SF, Villacres MC, Markel S, et al (2004) Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104:847-856
34. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399-1405
35. La Rosa C, Wang Z, Lacey SF, Lalimarmo MM, Krishnan A, Longmate J, et al (2006) In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp Hematol 34:497-507
36. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216-1224
37. Carbone DP, Ciernik IF, Kelley MJ, Smith MC, Nadaf S, Kavanaugh D, et al (2005) Immunization with mutant p53-and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23:5099-5107
38. van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, et al (2002) Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 8:1019-1027
39. Luo JL, Tong WM, Yoon JH, Hergenhahn M, Koomagi R, Yang Q, et al (2001) UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 61:8158-8163
40. Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JD (1997) The use of transgenic mice to generate high affinity p53-specific cytolytic T cells. J Surg Res 69:337-343
41. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833-841
42. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327
43. Lane DP (1999) Exploiting the p53 pathway for cancer diagnosis and therapy. Br J Cancer 80(Suppl 1):1-5
44. Bertholet S, Iggo R, Corradin G (1997) Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 27:798-801
45. Theobald M, Biggs J, Dittmer D, Levine A, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993-11997
46. Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C, et al (2000) Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 30:1676-1682
47. Sherman LA, Burke TA, Biggs JA (1992) Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med 175:1221-1226